Anebulo Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Net Income	-7.69	-8.2	-11.73	-6.83	-30.25	-1.05
Other Amortization	0.42	0.15	-	-	-	-
Stock-Based Compensation	1.28	0.76	0.88	0.48	0.2	-
Other Operating Activities	-	-	-	-	26.63	0.01
Change in Accounts Receivable	-	-	-	-	0	-
Change in Accounts Payable	0.04	-0.38	0.15	0.27	0.11	-
Change in Other Net Operating Assets	-0.81	-0.42	1.01	0.64	-1.56	0.14
Operating Cash Flow	-6.75	-8.09	-9.68	-5.44	-4.87	-0.9
Total Debt Issued	-	-	-	-	-	1.2
Short-Term Debt Repaid	-	-	-	-	-0.2	-
Total Debt Repaid	-	-	-	-	-0.2	-
Net Debt Issued (Repaid)	-	-	-	-	-0.2	1.2
Issuance of Common Stock	15	-	6.7	-	20.6	-
Other Financing Activities	-0.12	-0.06	-0.32	-	1.43	-0.15
Financing Cash Flow	14.88	-0.06	6.38	-	21.83	19.05
Net Cash Flow	8.13	-8.15	-3.3	-5.44	16.96	18.15
Cash Interest Paid	-	-	-	-	0.01	-
Levered Free Cash Flow	-5	-5.18	-5.32	-2.88	-3.51	-
Unlevered Free Cash Flow	-5.16	-5.23	-5.32	-2.88	-3.5	-
Change in Net Working Capital	0.77	0.8	-1.16	-0.91	1.45	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q